# A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

> **NCT03739840** · PHASE3 · TERMINATED · sponsor: **UCB Biopharma SRL** · enrollment: 232 (actual)

## Conditions studied

- Drug-Resistant Epilepsy
- Focal-Onset Seizures

## Interventions

- **DRUG:** Padsevonil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03739840
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-06
- **Primary completion:** 2020-09-28
- **Final completion:** 2020-09-28
- **Target enrollment:** 232 (ACTUAL)
- **Why stopped:** Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure
- **Last updated:** 2022-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03739840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03739840, "A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03739840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*